Cargando…
Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease
Alzheimer’s disease (AD) is increasingly prevalent worldwide, and disease‐modifying treatments may soon be at hand; hence, now, more than ever, there is a need to develop techniques that allow earlier and more secure diagnosis. Current biomarker‐based guidelines for AD diagnosis, which have replaced...
Autores principales: | Alawode, D. O. T., Heslegrave, A. J., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O´Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., Keshavan, A., Snellman, A., Gobom, J., Paterson, R. W., Schott, J. M., Blennow, K., Fox, N. C., Zetterberg, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416781/ https://www.ncbi.nlm.nih.gov/pubmed/34021943 http://dx.doi.org/10.1111/joim.13332 |
Ejemplares similares
-
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022) -
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
por: Grothe, Michel J., et al.
Publicado: (2021) -
Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021) -
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020) -
Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
por: Smirnov, Denis S., et al.
Publicado: (2022)